Causal associations between plasma proteins and prostate cancer: a Proteome-Wide Mendelian Randomization

Chen Lin[1] , Gu Yanlun[1,2] , Chen Yuke[3], Yu Wei[3] , Zhou Ying[1*] , Rong Zhuona[1*] , Pang Xiaocong[1*]

[1] Department of Pharmacy, Peking University First Hospital, Xishiku Street, Xicheng District, 100034 Beijing, China

[2] School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Haidian District, 100191 Beijing, China

[3] Department of Urology, Peking University First Hospital, Xishiku Street, Xicheng District, 100034 Beijing, China

*Corresponding author.

Abstract

Background:

Due to the limitations in specificity of current diagnostic methods for prostate cancer (PCa), more reliable biomarkers are needed to explore for improving early detection. Plasma proteins represent a promising source of biomarkers, therefore understanding the causal relationships between specific plasma proteins and PCa could be conductive to identify novel biomarkers and therapeutic targets for PCa prevention and treatment.

Methods:

We performed a meta-analysis of two independent genome-wide association studies (GWASs) including 94,397 individuals with PCa and 192,372 controls. A mendelian

randomization (MR) supplemented by colocalization analysis was conducted, using *cis*-acting variants on 4,907 plasma proteins from deCODE Genetics (N=35,559) and 2,940 plasma proteins from UK Biobank Pharma Proteomics Project (UKB-PPP) (N=54,219). Then, the biological pathway analysis and druggability evaluation of the risk proteins were further performed.

Results:

Five possible susceptibility loci (JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3) for PCa were identified through the meta-analysis of GWASs. Among 3,722 plasma proteins, 193 proteins were associated with PCa risk, of which 20 high-risk proteins, including KLK3, were validated in both the deCODE and UKB-PPP cohorts. Functional annotation of these genes encoding proteins confirmed enrichment of immune response, inflammatory response, cell-cell interaction and so on. Genetic colocalization and druggable genome analyses also identified several potential drug targets for PCa, such as HSPB1, RRM2B and PSCA.

Conclusions:

We identified novel variants as well as several protein biomarkers linked to PCa risk and indicated pathways associated with PCa, which offered new insights into PCa etiology and contributed to development of novel biomarkers for early detection and potential therapeutic interventions.

Funding:

This work was supported by grants from Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038, No. L248076) and National Natural

Science Foundation of China (grant No. 82274015).

Keywords: Prostate cancer, Proteins, Biomarkers, Mendelian randomization, Colocalization analysis

Graphical abstract: A comprehensive study design summarized as follows.

Introduction

Prostate cancer (PCa) is the second most common malignancy with an estimation of 1.5 million new cases in 2022, which is account for 14% of total cancer diagnosed in men worldwide(Ferlay J, 2024). Even more worrying is that the number of new cases of PCa are projected to 2.9 million by 2040(James et al., 2024). Despite advancements in medical technology, early detection of PCa remains a significant challenge due to the limitations in specificity of current diagnostic methods, such as prostate-specific antigen (PSA) testing.(Kalavacherla et al., 2023; Tikkinen et al., 2018) Therefore, there is an urgent need for more accurate and reliable biomarkers that can improve early detection and prognostic evaluations of PCa.

Plasma proteins have key roles in the development and progression of PCa, such as interleukin (IL)-6(Deichaite et al., 2022), insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-1(Cao et al., 2015). However, observational studies exploring the association between plasma proteins and PCa risk are often limited by confounding factors and selection bias, making it challenging to establish a clear causal relationship.

To overcome these limitations, Mendelian randomization (MR) offers a robust methodological approach. This approach utilizes the principle of random assortment of genes from parents to offspring, using genetic variation as an instrumental variable, which mimics the randomization process in a controlled trial, thereby minimizing the impact of reverse causality(Davies, Holmes, & Smith, 2018). With the recent development of proteomics technology, several large-scale proteomic studies have

identified over 18,000 protein quantitative trait loci (pQTLs) covering more than 4800 proteins(Ferkingstad et al., 2021; Pietzner et al., 2021). By using MR, researchers can gain a deeper comprehension of whether particular plasma proteins hold a causal nexus with PCa, thereby potentially unraveling novel biomarkers and targets for the prevention and treatment of PCa.

In this study, we performed a meta-analysis of two genome-wide association studies (GWAS) on PCa (PRACTICAL and FinnGen) for a total sample size of 94,397 cases and 192,372 controls. Based on GWAS summary statistics data from deCODE and UKB-PPP cohorts, we further performed a protein-wide MR (PW-MR) study, supplemented by colocalization analysis, to explore the casual relationship between plasma proteins and PCa risk. Moreover, we indicated biological processes and pathways associated with PCa, and evaluated the druggability of risk proteins. We aimed to identify novel plasma proteins biomarkers for PCa, which could address the limitations of current diagnostic methods and offer new insights into the biological mechanisms of PCa and potential therapeutic targets for intervention.

Methods

Data sources for plasma proteins

We selected *cis*-SNPs associated with plasma proteins as instrumental variables from two large-scale GWASs in the deCODE Genetics(Ferkingstad et al., 2021) and UKB-PPP(Sun et al., 2023). Cis-SNPs were defined as SNPs within a vicinity of ±1 Mb around the gene encoding the protein. From these SNPs, only those with a minor allele frequency of ≥ 1% that were genome-wide significance ($p < 5×10^{-8}$) and considered independent (linkage disequilibrium $r^2 < 0.1$ in 1000G) were retained. deCODE Genetics conducted proteomic profiling on blood plasma samples from 35,559 Icelanders using the SomaScan platform and collected data on 4907 aptamers(Ferkingstad et al., 2021). For the two-sample MR analysis, we selected cis-SNPs as instrumental variables for 1778 proteins. Likewise, cis-SNPs for 1944 plasma proteins were obtained from the UKB-PPP where 2940 proteins were measured among 54,219 Europeans using the Olink platform(Sun et al., 2023). The proteins with positive MR results were included in the colocalization analysis.

Data sources for Prostate Cancer

GWAS summary statistics for PCa were obtained from the PRACTICAL consortium(Schumacher et al., 2018) and FinnGen study. The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) consortium included 79,198 cases and 61,106 controls. We used the data on PCa from the FinnGen study R10 in this analysis, which comprised 15,199 cases and 131,266 controls. All participants of these two cohorts were of European ancestry. In

the MR analysis, we treated the PRACTICAL consortium as the discovery study and the FinnGen R10 study as the replication. To increase the effectiveness, we performed a fixed-effect GWAS meta-analysis of the two GWASs using the METAL package. The quantile-quantile plot was generated using the "qqman" package in R software (4.3.3). The R package "gassocplot" was used to plot regional association plots for the top SNP at each of the genome-wide significant loci identified.

Cross-phenotype analysis

Through the interactive Cross-Phenotype Analysis of GWAS database (iCPAGdb)(Wang et al., 2020), a new platform for cross-phenotype analysis, we explored the genetic correlation between PCa and other traits. We analyzed the genetic correlations between PCa and 3793 traits using data from the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) GWAS catalog(Wang et al., 2020). Through the use of ancestry LD-specific association data, iCPAGdb performs cross-phenotype enrichment analyses. iCPAGdb reveals signals of pairwise traits and shared signals by analyzing traits associations with LD proxy SNPs. The output data will show results from Fisher's exact test with adjustment for 5% false discovery rate (FDR) and also Bonferroni's, Jaccard's, Sorensen's, and Chao-Sorensen similarity indexes.

MR analysis

We conducted a MR analysis with plasma proteins as the exposure variable and PC as the outcome variable. We utilized the R package "TwoSampleMR" in R software (4.3.3) for the MR analysis. When only one SNP was available for a particular protein,

we applied the Wald ratio test. Inverse-variance weighted (IVW) was used as the main analysis method for two or more SNPs available. Considering multiple testing, we employed the 5% False Discovery Rate (FDR) method for P-value correction. P<0.05 was considered statistically significant. MR-Egger and weighted median methods were used as supplementary analysis methods. Cochran's Q statistic test using the MR-Egger method was used to determine the heterogeneity between the genetic variants. We also performed MR-Egger regression intercept to detect and adjust the directional horizontal pleiotropy(Hemani, Bowden, & Smith, 2018), P<0.05 was considered as the presence of directional pleiotropy and thus removed from the further analyses.

Colocalization analysis

The "coloc" package was used to perform Bayesian colocalization analysis to investigate if the associations between plasma proteins and PCa were driven by linkage disequilibrium (LD) (Giambartolomei et al., 2014). For proteins with positive MR results, the Bayesian method assessed the support for the following five exclusive hypotheses: 1) no association with either trait; 2) association with trait 1 only; 3) association with trait 2 only; 4) both traits are associated, but distinct causal variants were for two traits; and 5) both traits are associated, and the same shares causal variant for both traits(Foley et al., 2021). The posterior probability is provided for each hypothesis (H0, H1, H2, H3, and H4). In this analysis, we set prior probabilities of the SNP being associated with trait 1 only (p1) at 1×10^{-4}; the probability of the SNP being associated with trait 2 only (p2) at 1×10^{-4}; and the probability of the SNP

being associated with both traits (p12) at 1×10^{-5}. Two signals were considered to have strong evidence of colocalization if the posterior probability for shared causal variants (PH4) was ≥ 0.8. The analysis was performed in R software (4.3.3).

Biological pathway analysis

The GENE2FUNC tool in FUMA(Watanabe, Taskesen, van Bochoven, & Posthuma, 2017) web application programming interface version 1.5.2 were used to investigate functional annotation and enrichment analysis of the genes coding for the 193 unique proteins identified by the PW-MR approach. This analysis involved calculating the log2 fold-change expression for each gene across 54 tissue types from the GTEx (Genotype-Tissue Expression) database. We conducted gene enrichment analysis to identify overrepresented biological processes using the GO (Gene Ontology) database, which helped determine the biological processes most relevant to the genes identified. To investigate the involvement of the identified genes in functional and signaling pathways, we used the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database. Enrichment results were considered significant if they passed 5% FDR P-value threshold. Additionally, only enrichments involving at least two overlapping genes with the gene sets were considered to ensure robustness and biological relevance.

Druggability evaluation

The analysis of drug targets for the significant proteins identified in the MR Analysis was conducted using data from OpenTargets(Ochoa et al., 2023) (v.22.11), which is publicly accessible. We selected all drugs for which there was evidence for an

association with the protein of interest.

Results

Meta-analysis of the Genome-Wide Association Studies for Prostate Cancer

We conducted a meta-analysis combing two GWAS studies with a collective sample size of 94,397 individuals with PCa and 192,372 controls, aiming to identify genetic variants linked to PCa. The associations and assessment of SNPs heterogeneity that passed the genome-wide P-value threshold at these loci with PCa were presented in Supplementary Table 1. We found 5 genetic risk loci contained at least one SNP passing the genome-wide significance threshold of $P \leq 5 \times 10^{-8}$: JAZF1, PDILM5, WDPCP, EEFSEC, and TNS3 (Figure 1). Among them, PDLIM5, WDPCP, EEFSEC and TNS3 were promising candidates as novel susceptibility loci associated with PCa. Supplementary Figure 1 displayed the associated quantile-quantile plot. The LocusZoom plots of the top SNPs at JAZF1, PDILM5, WDPCP, EEFSEC and TNS3, along with their genomic location, GWAS P values and recombination rate with neighboring SNPs were visualized in Supplementary Figure 2. In summary, this GWAS meta-analysis discovered genetic variations in one recognized PC-associated loci and four potential novel loci, providing a reliable dataset for MR analyses.

Cross-phenotype Analysis of Prostate Cancer

The cross-phenotype analysis was designed to systematically identify phenotypic traits that share genetic or molecular pathways with PCa, thereby uncovering pleiotropic mechanisms or shared risk factors. We used the iCPAGdb to conduct this analysis with PCa genome-wide significant SNPs ($P \leq 5 \times 10^{-8}$). The iCPAGdb offered an improved algorithm for identifying cross-phenotype associations by using pre-

computed ancestry-specific LD databases and integrating genetic data from 3793 traits in the NHGRI-EBI GWAS catalog(Wang et al., 2020). Cross-phenotype analysis of PCa-associated SNPs identified 117 traits significantly linked to PCa after Bonferroni's correction(Supplementary Table 2). As shown in Figure 2, the strong association with PSA measurement ($P=7.16\times10^{-43}$) validated our genetic instruments, while the enrichment of metabolic traits such as BMI-adjusted waist-hip ratio (WHR) ($P=1.32\times10^{-26}$), high density lipoprotein (HDL) cholesterol measurement ($P=2.38\times10^{-22}$) and body mass index ($P=1.71\times10^{-20}$) aligned with epidemiological evidence linking obesity to aggressive PCa. Notably, the strong association with balding ($P=3.01\times10^{-22}$) reinforced the androgen axis in PCa pathogenesis and the correlation with heel bone mineral density ($P=2.02\times10^{-19}$) was consistent with the clinical observations of osteoblastic bone metastasis in advanced PCa. These cross-phenotype associations collectively highlight PCa as a systemic disorder involving androgen signaling, metabolic dysregulation and skeletal interactions, providing novel insights into its multifactorial etiology.

Proteome-Wide Mendelian Randomization Studies of Prostate Cancer

The genetic association summary statistics of 35,559 Icelanders from deCODE Genetics and 54,219 Europeans from the UKB-PPP were utilized to investigate the relationship between PCa and plasma proteins. Our genetic instrument selection strategy enabled us to examine 1778 and 1944 proteins from deCODE and UKB-PPP (Supplementary Table 3A and B). Using the Wald ratio or IVW method, a total of 193 unique plasma proteins were significantly associated with PCa after multiple tests

with a 5% FDR correction. This analysis yielded 137 proteins in UKB-PPP more than 76 proteins in deCODE (Figure 3A). The results of Heterogeneity test based on Q statistics showed little evidence of heterogeneity. Furthermore, no significant intercept was detected, implying that there was no directional pleiotropy observed.

After FDR correction, 20 proteins were detected in both data sets and the identified associations were consistent (Figure 3B). Genetic prediction indicated that 11 of these 20 proteins were positively associated with the risk of PCa as well as remaining 9 proteins were negatively associated, suggesting that these 9 proteins maybe protective factors against PCa (Supplementary Table 4). A PhenoGram depicted the chromosomal location of the 193 unique identified proteins in deCODE and UKB-PPP studies (Figure 3C).

Colocalization analysis

We performed colocalization analyses of proteins significantly expressed in deCODE and UKB-PPP studies with PCa. It was observed that 4 proteins in deCODE study and 7 proteins in UKB-PPP were colocalized with PCa associations with high support of evidence (PPH4 ≥ 0.8) (Table 1), suggesting that these 10 plasma proteins might serve as potential targets for treating PCa. Among them, SERPINA3 showed strong colocalization evidence in both decode (PPH4=0.952) and UKB-PPP (PPH4=0.951) studies. This analysis identified 1 causal variant in deCODE (rs61976125) and 1 causal variant in Fenland (rs6575449) (Figure 4).

Table 1. Analysis of Mendelian randomization and colocalization of significant proteins with PCa.

GWAS	Outcomes	Proteins	Mendelian randomization			Colocalization
			OR (95%CI)	P value	P value after FDR adjustment	Analysis PH4
deCODE	Prostate Cancer	MSMB	0.86(0.84,0.88)	1.56E-27	2.82E-24	0.999
		POGLUT3	0.89(0.83,0.96)	1.16E-03	2.44E-02	0.998
		PRSS3	0.93(0.91,0.94)	1.00E-18	6.03E-16	0.956
		SERPINA3	1.11(1.06,1.15)	7.18E-08	1.05E-05	0.952
UKB-PPP	Prostate Cancer	USP28	0.47(0.40,0.56)	7.27E-17	2.89E-14	0.999
		KLK3	9.70(4.94,19.03)	3.83E-11	6.91E-09	0.999
		IGFBP3	1.07(1.05,1.09)	2.04E-11	4.49E-09	0.997
		CASP10	1.22(1.11,1.34)	4.73E-05	1.54E-03	0.988
		HDGF	0.96(0.95,0.97)	2.61E-17	1.29E-14	0.966
		SERPINA3	1.10(1.07,1.13)	1.64E-10	2.32E-08	0.951
		C5	1.19(1.11,1.27)	5.32E-07	4.06E-05	0.883

OR, odds ratio; CI, confidence interval; FDR, false discovery rate.

Gene-Based Association and Pathway Analyses

We used the GENE2FUNC tool available in FUMA to explore the biological significance, functional implications and tissue-specific expression of the genes identified from our GWAS. These genes appeared to be significantly enriched in inflammatory and immune pathways (such as defense, immune and inflammatory response), as well as cell interaction and signaling pathways (such as interaction between organism and cell adhesion) (Figure 5A). The KEGG pathway enrichment analysis revealed several pathways that were significantly enriched, such as cytokine-cytokine receptor interaction, p53 signaling pathway, JAK-STAT signaling pathway, pathways in cancer and apoptosis (Figure 5B). These analyses indicated potential biological processes and mechanisms associated with PCa. The 193 unique genes were predominantly expressed in the lymphocytes, blood, liver and prostate (Supplementary Figure 3).

Druggability of identified proteins

Exploring new therapeutic opportunities for PCa based on genetic information is crucial for developing targeted treatments. In our study, we examined the druggability of genes and proteins identified in MR analyses using OpenTargets databases. We investigated 128 unique drugs targeting 45 identified proteins (Supplementary Table 5). Among these, three drugs (APATORSEN, TRIAPINE and MK-4721) currently in clinical trials were intended for PCa treatment, with each targeting HSPB1, RRM2B and PSCA, respectively. Notably, the effects of these drugs on their respective protein targets align with the directions indicated by our MR results, suggesting a consistency

between genetic evidence and therapeutic potential. In addition, several other identified targets, such as RET, FGFR3, NCAM1, TYMP, TNFRSF10B, MMP3, TACSTD2 and NOTCH2, were implicated in various cancers and present potential therapeutic avenues.

Discussion

Genetic Susceptibility Loci and Functional Mechanisms

In this study, we conducted a comprehensive meta-analysis of two GWAS for PCa, identifying significant genetic loci associated with PCa risk. The combined sample size of 94,397 cases and 192,372 controls revealed one known (JAZF1) and four potential novel (PDLIM5, WDPCP, EEFSEC and TNS3) susceptibility loci of PCa. These genetic findings not only expand our understanding of PCa heritability but also bridge the gap between genetic risk and downstream molecular mechanisms.

JAZF1, a transcriptional repressor linked to metabolic regulation(Rosario et al., 2023) and cellular proliferation(Sung et al., 2018), has been implicated in both type 2 diabetes and PCa risk through GWAS studies(Machiela et al., 2012; Sánchez-Maldonado et al., 2022). Its dual role highlights the interaction between metabolic dysregulation and oncogenesis, indicating that interventions targeting metabolic pathways may hold therapeutic promise for PCa.

PDLIM5 (PDZ and LIM domain 5), a cytoskeleton-associated protein, regulates cell migration and tumor progression by binding a variety of proteins through its specific domains. In PCa, PDLIM5 promotes epithelial-mesenchymal transition and migration of prostate cancer cells(Liu et al., 2017), while downregulating the expression of PDLIM5 may ultimately impede the progression of PCa(Xie et al., 2020), indicating its potential value in predicting the risk of advanced PCa. WDPCP, a key effector of planar cell polarity (PCP) signaling, regulates actin cytoskeleton to maintain tissue architecture.(Cui et al., 2013) Disruption of PCP signaling can cause abnormal cell

behavior and tissue structure, leading to the development of cancer.(Humphries & Mlodzik, 2018) EEFSEC is a member of the eukaryotic family of elongation factors and its role in tumor cells has been rarely reported. A functional study demonstrated that EEFSEC was significantly upregulated in PCa cells and high expression of EEFSEC was associated with poor prognosis in patients with PCa.(Xu et al., 2021) TNS3 promotes cell migration and invasion through focal adhesion dynamics(Chen et al., 2017; Martuszewska et al., 2009; Zheng et al., 2021; Zuidema et al., 2022), which is critical in cancer metastasis. While these loci implicate diverse pathways, their collective impact may converge on tumor microenvironment (TME) reprogramming. To certain whether these 4 genes causative factors for PCa, genetic association studies with a larger sample size will be needed.

Multifactorial Drivers of Prostate Cancer

PCa arises from a complex interplay of genetic, metabolic and hormonal perturbations. In the cross-phenotype Analysis of PCa, we found multiple risk-associated traits including proteomic biomarkers (PSA), metabolic dysregulation (central obesity, HDL dysfunction, hypertension) and androgen signaling (balding), collectively underscoring PCa's multifactorial etiology.

PSA, a protein secreted by both normal and malignant prostate epithelial cells, has long been a cornerstone in the early detection and monitoring of PCa. However, the specificity and sensitivity of PSA as a diagnostic tool have been questioned due to its elevation in benign conditions such as prostatitis and benign prostatic hyperplasia (BPH), leading to unnecessary biopsies and substantial overdiagnosis.(Gudmundsson

et al., 2018; Ilic et al., 2018; Kalavacherla et al., 2023) Therefore, complementary biomarkers are urgently needed to improve diagnostic accuracy. Our PW-MR study revealed that genetically plasma MSMB levels were causally associated with PCa risk. Importantly, this aligns with clinical utility of urinary MSMB: a quadriplex urine panel (MSMB, TRPM8, AMACR, PCA3) improved diagnostic accuracy in PCa patients compared to PSA alone.(Jamaspishvili et al., 2011) While plasma MSMB reflects systemic risk, urinary MSMB captures localized prostate pathology, together offering complementary insights into PCa biology. In conclusion, systematic integration of proteomic biomarkers identified through causal inference frameworks with PSA-based screening offers a path to resolve the persistent challenges of PCa diagnostic accuracy.

Emerging evidence implicates metabolic syndrome (MetS), which encompasses a cluster of conditions including central obesity, dyslipidemia and hypertension, may be a risk factor of PCa and may also worsen outcomes.(Hernandez-Perez et al., 2022; Lifshitz, Ber, & Margel, 2021) The significant association between BMI-adjusted WHR and advanced PCa risk suggested that central obesity may play a critical role in the development of PCa.(Genkinger et al., 2020; Perez-Cornago, Dunneram, Watts, Key, & Travis, 2022) Visceral adiposity may increase risk of advanced forms of PCa through changes in cytokines and growth factors, hormone regulation and metabolism.(Doyle, Donohoe, Lysaght, & Reynolds, 2012; Himbert et al., 2017) These metabolic perturbations extend beyond obesity itself, intersecting with broader lipid and inflammatory pathways that further modulate PCa risk. For instance, HDL

cholesterol, while classically recognized for its cardioprotective roles in reverse cholesterol transport and antioxidant and anti-inflammatory activities(Rohatgi, Westerterp, von Eckardstein, Remaley, & Rye, 2021), may also antagonize prostate carcinogenesis. Epidemiological and preclinical studies found that HDL may suppress prostate carcinogenesis by reducing oxidative stress and the levels of pro-inflammatory molecules in cancer cells and TME.(Ossoli, Wolska, Remaley, & Gomaraschi, 2022; Ruscica et al., 2018) However, in obesity, HDL's antioxidant and anti-inflammatory capacity is impaired due to altered composition and reduced functionality(Bacchetti, Morresi, Simonetti, & Ferretti, 2024), while adipose-derived ROS and cytokines further amplify oxidative damage(Balan, Halatiu, & Scridon, 2024). The loss of HDL protection and obesity-driven oxidative stress provides a physiological mechanistic basis for obesity-associated PCa aggressivity. This metabolic-inflammatory axis extends to hypertension, which is another MetS hallmark. Although results from previous studies of the association between hypertension and PCa development remain inconsistent(Christakoudi et al., 2020; Liang et al., 2016; Seretis et al., 2019), a MR analysis suggested that elevated systolic blood pressure might increase PCa risk through systemic inflammation(Stikbakke et al., 2022), a mechanism similar to that of central obesity and HDL dysfunction. Chronic inflammation contributes to a pro-tumorigenic environment by promoting cellular proliferation, DNA damage and resistance to apoptosis(Mantovani, Allavena, Sica, & Balkwill, 2008). Thus, MetS components likely converge on overlapping pathways to accelerate PCa progression, though the precise relationship between

systolic blood pressure and PCa remains unclear. More research is needed to elucidate the exact biological pathways involved and to determine whether managing clinical features of MetS could serve as a preventive strategy for PCa.

The link between androgenic alopecia (AGA) and PCa risk further implicates androgen metabolism as a central driver, as both conditions are influenced by dihydrotestosterone (DHT) levels. In AGA, DHT binds to androgen receptors (AR) in the dermal papilla cells, causing follicular miniaturization and hair loss.(Urysiak-Czubatka, Kmiec, & Broniarczyk-Dyla, 2014) Similarly, DHT-driven AR activation in prostate epithelial cells promotes proliferation and inhibits apoptosis, fostering tumorigenesis.(Tong et al., 2022) However, the link between AGA and PCa may not be solely hormone-dependent. Genetic pleiotropy where variants in loci such as AR or SRD5A2 influence both balding and prostate carcinogenesis, which could partially explain this association.(Hayes et al., 2005; Hayes et al., 2007) Further studies are needed to confirm the causality.

Overall, our cross-phenotype analysis provided a comprehensive view of the diverse factors associated with PCa and enhanced our understanding of the disease's multifaceted nature. Future researches should focus on elucidating the underlying mechanisms of these associations and exploring their potential for integration into clinical practice.

Plasma Proteins Causal Links to Prostate Cancer

The PW-MR study supplemented by colocalization analysis identified 193 unique proteins causally associated with PCa, including 10 with robust colocalization

evidence. These findings pinpoint both established and novel protein mediators of PCa pathogenesis, offering actionable insights into diagnostic and therapeutic innovation.

Microseminoprotein-beta (MSMB), the second most abundant prostate-secreted protein after PSA,(Lilja & Abrahamsson, 1988) has been shown to control prostate cell growth by regulating apoptosis(Garde et al., 1999). Unlike PSA, MSMB expression is not directly regulated by androgens. This androgen independence makes it possible for MSMB to be a supplementary biomarker for PSA, particularly in contexts where androgen receptor signaling is dysregulated, such castration-resistant prostate cancer (CRPC).(Sjöblom et al., 2016) Our study found that MSMB demonstrated the strongest protective association, and this findings was validated in prospective studies(Byrne et al., 2019; Haiman et al., 2013), supporting a potential protective role of MSMB in PCa. Some studies reported the level of MSMB in benign prostate tissues or BPH was significantly elevated and decreased or lost in PCa(Luebke et al., 2019; Nam et al., 2006; Whitaker, Warren, Eeles, Kote-Jarai, & Neal, 2010), however, others paradoxically observed that the decreased expression of MSMB was both in the tumor (especially in more advanced tumor) and adjacent benign prostate tissue(Bergström, Järemo, Nilsson, Adamo, & Bergh, 2018). This apparent discrepancy may reflect dynamic compensatory regulation during disease progression. In early carcinogenesis, benign epithelia adjacent to low-grade tumors may upregulate MSMB as a protective response to counteract oncogenic stress, whereas advanced tumors drive epigenetic silencing of MSMB, propagating a

permissive microenvironment for invasion. Overall, these findings position MSMB as a promising biomarker, which is expected to enhance the diagnostic and prognostic specificity of PCa through integration with PSA.

SERPINA3 is an inhibitor of serine proteases that was previously found to be upregulated in various types of cancer and its elevation was associated with a worse prognosis.(De Mezer et al., 2023) Mechanistically, SERPINA3 is regulated by inflammatory cytokines so that its expression is increased in the inflammatory response(Péré-Brissaud et al., 2015), may drive tumor progression. SERPINA3 emerged as a significant risk factor for PCa in our MR analysis, which aligns with several proteomics.(Nguyen et al., 2018; Zhang et al., 2022) The overexpression of SERPINA3 indicates that damage tends to occur in the body contributing to decreased cell adhesion ability and inhibition of apoptosis.(Chelbi et al., 2012) These alterations may synergistically enhance metastatic potential, as evidenced by a recent study linking SERPINA3 to bone metastasis. A study identified that the enhanced expression of SERPINA3 stimulated the bone environment by promoting osteoblasts and osteoclasts activation, suggesting it may serve a diagnostic biomarker for PCa with bone metastasis phenotype and survival(Ito et al., 2023).

PRSS3, also named mesotrypsin, is reported to be aberrantly expressed in various types of tumors and participates in the progression and development of cancers. For example, PRSS3 was identified to be downregulated in lung cancer(Zhou, Li, & Luo, 2023) but upregulated in pancreatic cancer(Jiang et al., 2010; Xing et al., 2019), suggesting it may have different roles depending on the cellular or disease ways. A

study demonstrated that PRSS3 was ectopically expressed in metastatic tissues of PCa and identified PRSS3 as a promising therapeutic target for metastatic PCa.(Hockla et al., 2012) The research of PRSS3 in PCa is relatively limited, further studies are necessary to fully understand the functions and mechanisms of PRSS3 in human PCa.

KLK3, which codes for PSA, is a well-known PCa biomarker. While its diagnostic utility is clinically validated, emerging evidences reveal that KLK3 mRNA detection in whole blood has a predictive role in tumor progression and therapeutic resistance, which is expected to become a potential prognostic marker for PCa.(Boerrigter et al., 2021; Cho et al., 2024) KLK3's canonical role as a serine protease involves cleaving extracellular matrix (ECM) components and activating matrix metalloproteinases to promote tumor invasion and metastasis.(Escaff et al., 2010; Moradi, Srinivasan, Clements, & Batra, 2019) Additionally, the androgen regulation of KLK3 expression correlated with the androgen receptor signaling pathway, a critical driver of PCa progression, particularly in CRPC.(Lilja, Ulmert, & Vickers, 2008) Despite these insights, the precise biological pathways through which KLK3 contributes to PCa progression remain incompletely understood. Further research is needed to illustrate the direct and indirect effects of KLK3 on PCa cells and TME.

Despite substantial preclinical efforts identifying numerous promising biomarkers, their translation into routine clinical application remains strikingly limited due to the lack of further validation. Therefore, prospective validation is important and crucial.

Biological Mechanisms and Druggable Targets

Our integrative analysis revealed that the 193 candidate genes identified through MR

were significantly enriched in inflammatory/immune pathways (e.g., cytokine-cytokine receptor interaction, JAK-STAT signaling) and cancer-related processes such as apoptosis and cell adhesion. These pathways not only depict the molecular landscape of PCa but also identify viable targets for therapeutic intervention.

For instance, RRM2B is a DNA repair enzyme targeted by the clinical-stage drug TRIAPINE, and its role in maintaining genomic stability under replicative stress is consistent with the enrichment of the p53 signaling pathway.(Elfar et al., 2024) Similarly, the cell adhesion pathways is central to metastatic dissemination. As a member of Thy-1/ Ly-6 family involved in cell adhesion and metastasis, PSCA's overexpression in high-grade PCa and metastatic lesions underscores the therapeutic potential of PSCA inhibitors in targeting tumor-stroma crosstalk to prevent metastatic spread.(Dizaj et al., 2024) Furthermore, HSPB1, a molecular chaperone implicated in apoptosis evasion and chemotherapy resistance(Garrido et al., 2006; Hadaschik et al., 2008; Kamada et al., 2007), aligns with the observed enrichment of survival pathways in aggressive PCa.(Shiota et al., 2013; Vasiljevic et al., 2013) The antisense oligonucleotide APATORSEN, which silences HSPB1, restores chemosensitivity by reactivating apoptotic signaling, offering a strategy for therapeutic resistance against CRPC.(Le et al., 2023) Beyond these prioritized targets, the druggability analysis uncovered broader therapeutic potential. Proteins like RET (enriched in JAK-STAT signaling) and FGFR3 (linked to pathways in cancer) are already targeted by approved therapies in other malignancies, suggesting rapid repurposing potential for PCa. In conclusion, bridging pathway enrichment with druggability data

transforms genetic associations into therapeutic hypotheses.

Study Strengths and Limitations

This study possessed several strengths, including the use of the largest collection of plasma protein data (coving more than 4800 proteins), large sample sizes of GWAS studies, a mutual validation across two independent outcome datasets and the use of colocalization analysis to support the MR results. Additionally, our assessment of the human blood proteome relied on two technologies (SOMAmer and Olink), which were valuable for identifying plasma proteins associated with diseases traits such as PCa.

Some limitations of our analysis should be acknowledged. Firstly, this investigation was only confined to Europeans, restricting the applicability of our findings to other populations. It is crucial for future studies to identify risk proteins in more diverse populations, especially African ancestry who face a higher risk of PCa. Secondly, our study concentrated on the proteins available in the MR analysis, which likely led to the omission of other potential therapeutic targets. Thirdly, we utilized proteomic data from Icelanders whose genetic backgrounds may differ from other European populations, which might introduce bias. Lastly, our analysis relied exclusively on publicly available GWAS summary statistics from openGWAS and FinnGen, which did not provide individual-level data on covariates, resulting in no direct assessment of demographic or clinical differences between cases and controls. However, this potential bias might be minimal, as we found that 20 proteins showing significance (P<0.05) in both the deCODE and UKB-PPP studies had consistent associations with

PCa.

In conclusion, we conducted a large-scale PW-MR study using the MR and colocalization analysis to investigate the genetic associations of up to 3,722 unique proteins with PCa. We revealed the complex genetic architecture of PCa and identified many new plasma proteins with strong causal associations to PCa. These findings highlighted the potential biomarkers for early detection and therapeutic targets, providing a foundation for future research and potential clinical applications.

Data availability

The GWAS summary statistics of blood pQTLs from deCODE can be found at https://www.decode.com/summarydata/, and those of the UKB-PPP can be found at https://www.synapse.org/#!Synapse:syn51365303. Summary statistics of PCa from the PRACTICAL consortium can be obtained from OpenGWAS (https://gwas.mrcieu.ac.uk/), and those of the FinnGen study can be obtained from https://r10.finngen.fi/. The OpenTargets data were downloaded directly from the OpenTargets website (https://platform.opentargets.org/downloads/data).

Acknowledgements

The authors would like to thank all the participants and investigators of the studies (PRACTICAL, FinnGen, deCODE, UKB-PPP) for providing the invaluable data used in this research. Their commitment and effort have been essential for the success of this study. Furthermore, special thanks to our colleagues and collaborators for their insightful discussions and feedback throughout the research process. This research was funded by Beijing Municipal Natural Science Foundation (grant No. JQ24059, No. L234038, No. L248076), and National Natural Science Foundation of China (grant No. 82274015).

Conflicts of interest

All authors declare that they have no conflicts of interest to disclose.

References

Bacchetti, T., Morresi, C., Simonetti, O., & Ferretti, G. (2024). Effect of Diet on HDL in Obesity. *Molecules, 29*(24), 17. doi:10.3390/molecules29245955

Balan, A. I., Halatiu, V. B., & Scridon, A. (2024). Oxidative Stress, Inflammation, and Mitochondrial Dysfunction: A Link between Obesity and Atrial Fibrillation. *Antioxidants, 13*(1), 21. doi:10.3390/antiox13010117

Bergström, S. H., Järemo, H., Nilsson, M., Adamo, H. H., & Bergh, A. (2018). Prostate tumors downregulate microseminoprotein-beta (MSMB) in the surrounding benign prostate epithelium and this response is associated with tumor aggressiveness. *Prostate, 78*(4), 257-265. doi:10.1002/pros.23466

Boerrigter, E., Benoist, G. E., van Oort, I. M., Verhaegh, G. W., van Hooij, O., Groen, L., . . . van Erp, N. P. (2021). Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. *Molecular Oncology, 15*(9), 2453-2465. doi:10.1002/1878-0261.12933

Byrne, K. S., Appleby, P. N., Key, T. J., Holmes, M. V., Fensom, G. K., Agudo, A., . . . Consortium, P. (2019). The role of plasma microseminoprotein-beta in prostate cancer: an observational nested case-control and Mendelian randomization study in the European prospective investigation into cancer and nutrition. *Annals of Oncology, 30*(6), 983-989. doi:10.1093/annonc/mdz121

Cao, Y., Nimptsch, K., Shui, I. M., Platz, E. A., Wu, K., Pollak, M. N., . . . Giovannucci, E. L. (2015). Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.

International Journal of Cancer, 136(10), 2418-2426. doi:10.1002/ijc.29295

Chelbi, S. T., Wilson, M. L., Veillard, A. C., Ingles, S. A., Zhang, J., Mondon, F., . . . Vaiman, D. (2012). Genetic and epigenetic mechanisms collaborate to control *SERPINA3* expression and its association with placental diseases. *Human Molecular Genetics, 21*(9), 1968-1978. doi:10.1093/hmg/dds006

Chen, H. Y., Lin, L. T., Wang, M. L., Laurent, B., Hsu, C. H., Pan, C. M., . . . Chiou, S. H. (2017). Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3. *Scientific Reports, 7*, 14. doi:10.1038/s41598-017-09504-7

Cho, H., Byun, S. S., Son, N. H., Chung, J. I., Seo, W. I., Lee, C. H., . . . Chung, J. S. (2024). Impact of Circulating Tumor Cell-Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer. *Clinical Cancer Research, 30*(9), 1788-1800. doi:10.1158/1078-0432.Ccr-23-3083

Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., . . . Tsilidis, K. K. (2020). Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer, 146*(10), 2680-2693. doi:10.1002/ijc.32576

Cui, C., Chatterjee, B., Lozito, T. P., Zhang, Z., Francis, R. J., Yagi, H., . . . Lo, C. W. (2013). Wdpcp, a PCP Protein Required for Ciliogenesis, Regulates Directional Cell Migration and Cell Polarity by Direct Modulation of the Actin Cytoskeleton. *Plos Biology, 11*(11), 17. doi:10.1371/journal.pbio.1001720

Davies, N. M., Holmes, M. V., & Smith, G. D. (2018). Reading Mendelian randomisation

studies: a guide, glossary, and checklist for clinicians. *Bmj-British Medical Journal, 362*, 11. doi:10.1136/bmj.k601

De Mezer, M., Rogalinski, J., Przewozny, S., Chojnicki, M., Niepolski, L., Sobieska, M., & Przystanska, A. (2023). SERPINA3: Stimulator or Inhibitor of Pathological Changes. *Biomedicines, 11*(1), 15. doi:10.3390/biomedicines11010156

Deichaite, I., Sears, T. J., Sutton, L., Rebibo, D., Morgan, K., Nelson, T., . . . Carter, H. (2022). Differential regulation of TNFα and IL-6 expression contributes to immune evasion in prostate cancer. *Journal of Translational Medicine, 20*(1), 16. doi:10.1186/s12967-022-03731-x

Dizaj, T. N., Doustmihan, A., Oskouei, B. S., Akbari, M., Jaymand, M., Mazloomi, M., & Jahanban-Esfahlan, R. (2024). Significance of PSCA as a novel prognostic marker and therapeutic target for cancer. *Cancer Cell International, 24*(1), 22. doi:10.1186/s12935-024-03320-6

Doyle, S. L., Donohoe, C. L., Lysaght, J., & Reynolds, J. V. (2012). Visceral obesity, metabolic syndrome, insulin resistance and cancer. *Proc Nutr Soc, 71*(1), 181-189. doi:10.1017/s002966511100320x

Elfar, G. A., Aning, O., Ngai, T. W., Yeo, P., Chan, J. W. K., Sim, S. H., . . . Cheok, C. F. (2024). p53-dependent crosstalk between DNA replication integrity and redox metabolism mediated through a NRF2-PARP1 axis. *Nucleic Acids Research, 52*(20), 12351-12377. doi:10.1093/nar/gkae811

Escaff, S., Fernández, J. M., González, L. O., Suárez, A., González-Reyes, S., González, J. M., & Vizoso, F. J. (2010). Study of matrix metalloproteinases and their inhibitors in

prostate cancer. *British Journal of Cancer, 102*(5), 922-929. doi:10.1038/sj.bjc.6605569

Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., . . . Stefansson, K. (2021). Large-scale integration of the plasma proteome with genetics and disease. *Nature Genetics, 53*(12), 1712-+. doi:10.1038/s41588-021-00978-w

Ferlay J, E. M., Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F . (2024). Global Cancer Observatory: Cancer Today. Retrieved from https://gco.iarc.who.int/today

Foley, C. N., Staley, J. R., Breen, P. G., Sun, B. B., Kirk, P. D. W., Burgess, S., & Howson, J. M. M. (2021). A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nature Communications, 12*(1), 18. doi:10.1038/s41467-020-20885-8

Garde, S. V., Basrur, V. S., Li, L., Finkelman, M. A., Krishan, A., Wellham, L., . . . Tang, D. G. (1999). Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cancer cell line (PC3) and xenografts by inducing apoptosis. *Prostate, 38*(2), 118-125. doi:10.1002/(sici)1097-0045(19990201)38:2<118::Aid-pros5>3.0.Co;2-g

Garrido, C., Brunet, M., Didelot, C., Zermati, Y., Schmitt, E., & Kroemer, G. (2006). Heat shock proteins 27 and 70. *Cell Cycle, 5*(22), 2592-2601. doi:10.4161/cc.5.22.3448

Genkinger, J. M., Wu, K., Wang, M., Albanes, D., Black, A., van den Brandt, P. A., . . . Smith-Warner, S. A. (2020). Measures of body fatness and height in early and mid-to-late

adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of Diet and Cancer. *Annals of Oncology, 31*(1), 103-114. doi:10.1016/j.annonc.2019.09.007

Giambartolomei, C., Vukcevic, D., Schadt, E. E., Franke, L., Hingorani, A. D., Wallace, C., & Plagnol, V. (2014). Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *Plos Genetics, 10*(5), 15. doi:10.1371/journal.pgen.1004383

Gudmundsson, J., Sigurdsson, J. K., Stefansdottir, L., Agnarsson, B. A., Isaksson, H. J., Stefansson, O. A., . . . Stefansson, K. (2018). Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. *Nature Communications, 9*, 8. doi:10.1038/s41467-018-06920-9

Hadaschik, B. A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H. M., Gleave, M. E., & So, A. I. (2008). Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer. *Bju International, 102*(5), 610-616. doi:10.1111/j.1464-410X.2008.07669.x

Haiman, C. A., Stram, D. O., Vickers, A. J., Wilkens, L. R., Braun, K., Valtonen-André, C., . . . Lilja, H. (2013). Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations. *Jnci-Journal of the National Cancer Institute, 105*(3), 237-243. doi:10.1093/jnci/djs486

Hayes, V. M., Severi, G., Eggleton, S. A., Padilla, E. J. D., Southey, M. C., Sutherland, R. L., . . . Giles, G. G. (2005). The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic

alopecia. *Cancer Epidemiology Biomarkers & Prevention, 14*(4), 993-996. doi:10.1158/1055-9965.Epi-04-0778

Hayes, V. M., Severi, G., Padilla, E. J. D., Morris, H. A., Tilley, W. D., Southey, M. C., . . . Giles, G. G. (2007). 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. *International Journal of Cancer, 120*(4), 776-780. doi:10.1002/ijc.22408

Hemani, G., Bowden, J., & Smith, G. D. (2018). Evaluating the potential role of pleiotropy in Mendelian randomization studies. *Human Molecular Genetics, 27*(R2), R195-R208. doi:10.1093/hmg/ddy163

Hernandez-Perez, J. G., Torres-Sanchez, L., Hernandez-Alcaraz, C., Lopez-Carrillo, L., Rodriguez-Covarrubias, F., Vazquez-Salas, R. A., & Galvan-Portillo, M. (2022). Metabolic Syndrome and Prostate Cancer Risk: A Population Case-control Study. *Archives of medical research, 53*(6), 594-602. doi:10.1016/j.arcmed.2022.07.003

Himbert, C., Delphan, M., Scherer, D., Bowers, L. W., Hursting, S., & Ulrich, C. M. (2017). Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review. *Cancer Prevention Research, 10*(9), 494-506. doi:10.1158/1940-6207.Capr-16-0322

Hockla, A., Miller, E., Salameh, M. A., Copland, J. A., Radisky, D. C., & Radisky, E. S. (2012). PRSS3/Mesotrypsin Is a Therapeutic Target for Metastatic Prostate Cancer. *Molecular Cancer Research, 10*(12), 1555-1566. doi:10.1158/1541-7786.Mcr-12-0314

Humphries, A. C., & Mlodzik, M. (2018). From instruction to output: Wnt/PCP signaling in

development and cancer. *Current Opinion in Cell Biology, 51*, 110-116. doi:10.1016/j.ceb.2017.12.005

Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., . . . Dahm, P. (2018). Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. *Bmj-British Medical Journal, 362*, 12. doi:10.1136/bmj.k3519

Ito, K., Yamamoto, T., Hayashi, Y., Sato, S., Nakayama, J., Urabe, F., . . . Yamamoto, Y. (2023). Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. *Molecular Oncology, 17*(10), 2147-2167. doi:10.1002/1878-0261.13484

Jamaspishvili, T., Kral, M., Khomeriki, I., Vyhnankova, V., Mgebrishvili, G., Student, V., . . . Bouchal, J. (2011). Quadriplex model enhances urine-based detection of prostate cancer. *Prostate Cancer and Prostatic Diseases, 14*(4), 354-360. doi:10.1038/pcan.2011.32

James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., . . . Xie, L.-P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. *Lancet (London, England), 403*(10437), 1683-1722. doi:10.1016/s0140-6736(24)00651-2

Jiang, G. Z., Cao, F. Y., Ren, G. P., Gao, D. L., Bhakta, V., Zhang, Y. H., . . . Wang, Y. H. (2010). PRSS3 promotes tumour growth and metastasis of human pancreatic cancer. *Gut, 59*(11), 1535-1544. doi:10.1136/gut.2009.200105

Kalavacherla, S., Riviere, P., Javier-DesLoges, J., Banegas, M. P., McKay, R. R., Murphy, J. D., & Rose, B. S. (2023). Low-Value Prostate-Specific Antigen Screening in Older

Males. *Jama Network Open, 6*(4), 12. doi:10.1001/jamanetworkopen.2023.7504

Kamada, M., So, A., Muramaki, M., Rocchi, P., Beraldi, E., & Gleave, M. (2007). Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. *Molecular Cancer Therapeutics, 6*(1), 299-308. doi:10.1158/1535-7163.Mct-06-0417

Le, T. K., Cherif, C., Omabe, K., Paris, C., Lannes, F., Audebert, S., . . . Rocchi, P. (2023). DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer. *Molecular Therapy, 31*(2), 471-486. doi:10.1016/j.ymthe.2022.08.005

Liang, Z., Xie, B., Li, J., Wang, X., Wang, S., Meng, S., . . . Xie, L. (2016). Hypertension and risk of prostate cancer: a systematic review and meta-analysis. *Scientific Reports, 6*, 31358. doi:10.1038/srep31358

Lifshitz, K., Ber, Y., & Margel, D. (2021). Role of Metabolic Syndrome in Prostate Cancer Development. *European Urology Focus, 7*(3), 508-512. doi:10.1016/j.euf.2021.04.022

Lilja, H., & Abrahamsson, P. A. (1988). 3 PREDOMINANT PROTEINS SECRETED BY THE HUMAN-PROSTATE GLAND. *Prostate, 12*(1), 29-38. doi:10.1002/pros.2990120105

Lilja, H., Ulmert, D., & Vickers, A. J. (2008). Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. *Nat Rev Cancer, 8*(4), 268-278. doi:10.1038/nrc2351

Liu, X., Chen, L., Huang, H., Lv, J. M., Chen, M., Qu, F. J., . . . Xu, D. F. (2017). High expression of PDLIM5 facilitates cell tumorigenesis and migration by maintaining AMPK activation in prostate cancer. *Oncotarget, 8*(58), 98117-98134.

doi:10.18632/oncotarget.20981

Luebke, A. M., Attarchi-Tehrani, A., Meiners, J., Hube-Magg, C., Lang, D. S., Kluth, M., . . . Höflmayer, D. (2019). Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of *PTEN* deleted prostate cancers. *Cancer Biology & Medicine, 16*(2), 319-330. doi:10.20892/j.issn.2095-3941.2018.0384

Machiela, M. J., Lindström, S., Allen, N. E., Haiman, C. A., Albanes, D., Barricarte, A., . . . Kraft, P. (2012). Association of Type 2 Diabetes Susceptibility Variants With Advanced Prostate Cancer Risk in the Breast and Prostate Cancer Cohort Consortium. *American Journal of Epidemiology, 176*(12), 1121-1129. doi:10.1093/aje/kws191

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. *Nature, 454*(7203), 436-444. doi:10.1038/nature07205

Martuszewska, D., Ljungberg, B., Johansson, M., Landberg, G., Oslakovic, C., Dahlbäck, B., & Hafizi, S. (2009). Tensin3 Is a Negative Regulator of Cell Migration and All Four Tensin Family Members Are Downregulated in Human Kidney Cancer. *Plos One, 4*(2), 13. doi:10.1371/journal.pone.0004350

Moradi, A., Srinivasan, S., Clements, J., & Batra, J. (2019). Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment. *Cancer and Metastasis Reviews, 38*(3), 333-346. doi:10.1007/s10555-019-09815-3

Nam, R. K., Reeves, J. R., Toi, A., Dulude, H., Trachtenberg, J., Emami, M., . . . Narod, S. A. (2006). A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at

diagnosis. *Journal of Urology, 175*(4), 1291-1297. doi:10.1016/s0022-5347(05)00695-6

Nguyen, E. V., Centenera, M. M., Moldovan, M., Das, R., Irani, S., Vincent, A. D., . . . Butler, L. M. (2018). Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. *Molecular & Cellular Proteomics, 17*(8), 1470-1486. doi:10.1074/mcp.RA118.000633

Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., . . . McDonagh, E. (2023). The next-generation Open Targets Platform: reimagined, redesigned, rebuilt. *Nucleic Acids Research, 51*(D1), D1353-D1359. doi:10.1093/nar/gkac1046

Ossoli, A., Wolska, A., Remaley, A. T., & Gomaraschi, M. (2022). High-density lipoproteins: A promising tool against cancer. *Biochimica Et Biophysica Acta-Molecular and Cell Biology of Lipids, 1867*(1), 11. doi:10.1016/j.bbalip.2021.159068

Péré-Brissaud, A., Blanchet, X., Delourme, D., Pélissier, P., Forestier, L., Delavaud, A., . . . Brémaud, L. (2015). Expression of SERPINA3s in cattle: focus on bovSERPINA3-7 reveals specific involvement in skeletal muscle. *Open Biology, 5*(9), 15. doi:10.1098/rsob.150071

Perez-Cornago, A., Dunneram, Y., Watts, E. L., Key, T. J., & Travis, R. C. (2022). Adiposity and risk of prostate cancer death: a prospective analysis in UK Biobank and meta-analysis of published studies. *Bmc Medicine, 20*(1), 13. doi:10.1186/s12916-022-02336-x

Pietzner, M., Wheeler, E., Carrasco-Zanini, J., Cortes, A., Koprulu, M., Wörheide, M. A., . . . Langenberg, C. (2021). Mapping the proteo-genomic convergence of human

diseases. *Science, 374*(6569), 839-+. doi:10.1126/science.abj1541

Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K. A. (2021). HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research. *Circulation, 143*(23), 2293-2309. doi:10.1161/circulationaha.120.044221

Rosario, S. R., Jacobi, J. J., Long, M. D., Affronti, H. C., Rowsam, A. M., & Smiraglia, D. J. (2023). JAZF1: A Metabolic Regulator of Sensitivity to a Polyamine-Targeted Therapy. *Molecular Cancer Research, 21*(1), 24-35. doi:10.1158/1541-7786.Mcr-22-0316

Ruscica, M., Botta, M., Ferri, N., Giorgio, E., Macchi, C., Franceschini, G., . . . Gomaraschi, M. (2018). High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation. *Scientific Reports, 8*, 12. doi:10.1038/s41598-018-19568-8

Sánchez-Maldonado, J. M., Collado, R., Cabrera-Serrano, A. J., Ter Horst, R., Gálvez-Montosa, F., Robles-Fernández, I., . . . Sainz, J. (2022). Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis. *Cancers, 14*(10), 23. doi:10.3390/cancers14102376

Schumacher, F. R., Al Olama, A. A., Berndt, S. I., Benlloch, S., Ahmed, M., Saunders, E. J., . . . Elucidating Loci Involved, P. (2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics, 51*(2), 363-363. doi:10.1038/s41588-018-0330-6

Seretis, A., Cividini, S., Markozannes, G., Tseretopoulou, X., Lopez, D. S., Ntzani, E. E., & Tsilidis, K. K. (2019). Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies.

Scientific Reports, 9(1), 8565. doi:10.1038/s41598-019-45014-4

Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., . . . Zoubeidi, A.
(2013). Hsp27 Regulates Epithelial Mesenchymal Transition, Metastasis, and
Circulating Tumor Cells in Prostate Cancer. *Cancer Research, 73*(10), 3109-3119.
doi:10.1158/0008-5472.Can-12-3979

Sjöblom, L., Saramäki, O., Annala, M., Leinonen, K., Nättinen, J., Tolonen, T., . . . Visakorpi,
T. (2016). Microseminoprotein-Beta Expression in Different Stages of Prostate
Cancer. *Plos One, 11*(3), 16. doi:10.1371/journal.pone.0150241

Stikbakke, E., Schirmer, H., Knutsen, T., Støyten, M., Wilsgaard, T., Giovannucci, E. L., . . .
Thune, I. (2022). Systolic and diastolic blood pressure, prostate cancer risk, treatment,
and survival. The PROCA-life study. *Cancer Med, 11*(4), 1005-1015.
doi:10.1002/cam4.4523

Sun, B. B., Chiou, J., Traylor, M., Benner, C., Hsu, Y. H., Richardson, T. G., . . . Whelan, C. D.
(2023). Plasma proteomic associations with genetics and health in the UK Biobank.
Nature, 622(7982), 329-338. doi:10.1038/s41586-023-06592-6

Sung, Y., Park, S., Park, S. J., Jeong, J., Choi, M., Lee, J., . . . Kim, M. O. (2018). Jazf1
promotes prostate cancer progression by activating JNK/Slug. *Oncotarget, 9*(1), 755-
765. doi:10.18632/oncotarget.23146

Tikkinen, K. A. O., Dahm, P., Lytvyn, L., Heen, A. F., Vernooij, R. W. M., Siemieniuk, R. A.
C., . . . Agoritsas, T. (2018). Prostate cancer screening with prostate-specific antigen
(PSA) test: a clinical practice guideline. *Bmj-British Medical Journal, 362*, 12.
doi:10.1136/bmj.k3581

Tong, Y., Guo, Y. J., Zhang, Q., Bi, H. X., Kai, K., & Zhou, R. Y. (2022). Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells. *Asian J Androl, 24*(5), 513-520. doi:10.4103/aja2021114

Urysiak-Czubatka, I., Kmiec, M. L., & Broniarczyk-Dyla, G. (2014). Assessment of the usefulness of dihydrotestosterone in the diagnostics of patients with androgenetic alopecia. *Postepy Dermatologii I Alergologii, 31*(4), 207-215. doi:10.5114/pdia.2014.40925

Vasiljevic, N., Ahmad, A. S., Beesley, C., Thorat, M. A., Fisher, G., Berney, D. M., . . . Lorincz, A. T. (2013). Association between DNA methylation of *HSPB1* and death in low Gleason score prostate cancer. *Prostate Cancer and Prostatic Diseases, 16*(1), 35-40. doi:10.1038/pcan.2012.47

Wang, L., Balmat, T. J., Antonia, A. L., Constantine, F. J., Henao, R., Burke, T. W., . . . Ko, D. C. (2020). An atlas connecting shared genetic architecture of human diseases and molecular phenotypes provides insight into COVID-19 susceptibility. *medRxiv : the preprint server for health sciences*. doi:10.1101/2020.12.20.20248572

Watanabe, K., Taskesen, E., van Bochoven, A., & Posthuma, D. (2017). Functional mapping and annotation of genetic associations with FUMA. *Nature Communications, 8*, 11. doi:10.1038/s41467-017-01261-5

Whitaker, H. C., Warren, A. Y., Eeles, R., Kote-Jarai, Z., & Neal, D. E. (2010). The Potential Value of Microseminoprotein-β as a Prostate Cancer Biomarker and Therapeutic Target. *Prostate, 70*(3), 333-340. doi:10.1002/pros.21059

Xie, P. B., Liu, M. S., Chen, F., Wu, S. M., Shao, T., Wang, W., . . . Zhou, H. Q. (2020). Long

Non-coding RNA AGAP2-AS1 Silencing Inhibits PDLIM5 Expression Impeding

Prostate Cancer Progression *via* Up-Regulation of MicroRNA-195-5p. *Frontiers in*

Genetics, 11, 13. doi:10.3389/fgene.2020.01030

Xing, C. J., Ye, H., Wang, W. W., Sun, M. M., Zhang, J. Y., Zhao, Z. H., & Jiang, G. Z. (2019).

Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by

sponging miR-217 and upregulating PRSS3 expression. *Artificial Cells Nanomedicine*

and Biotechnology, 47(1), 3920-3928. doi:10.1080/21691401.2019.1671856

Xu, B., Hao, J., Xie, Q., Sa, N., Wang, S., Du, X., . . . Dong, X. (2021). EEFSEC knockdown

inhibits proliferation, migration and invasion of prostate cancer cells in vitro. *Nan fang*

yi ke da xue xue bao = Journal of Southern Medical University, 41(12), 1787-1794.

doi:10.12122/j.issn.1673-4254.2021.12.05

Zhang, H., Zhang, G. Y., Su, W. C., Chen, Y. T., Liu, Y. F., Wei, D., . . . Yu, E. Y. W. (2022).

High Throughput Isolation and Data Independent Acquisition Mass Spectrometry

(DIA-MS) of Urinary Extracellular Vesicles to Improve Prostate Cancer Diagnosis.

Molecules, 27(23), 17. doi:10.3390/molecules27238155

Zheng, J. Y., Wang, C. Y., Gao, C., Xiao, Q., Huang, C. W., Wu, M., & Li, L. Y. (2021). MLL3

suppresses tumorigenesis through regulating TNS3 enhancer activity. *Cell Death &*

Disease, 12(4), 13. doi:10.1038/s41419-021-03647-2

Zhou, M. Y., Li, K. K., & Luo, K. Q. (2023). Shear Stress Drives the Cleavage Activation of

Protease-Activated Receptor 2 by PRSS3/Mesotrypsin to Promote Invasion and

Metastasis of Circulating Lung Cancer Cells. *Advanced Science, 10*(25), 21.

doi:10.1002/advs.202301059

Zuidema, A., Atherton, P., Kreft, M., Hoekman, L., Bleijerveld, O. B., Nagaraj, N., . . .
Sonnenberg, A. (2022). PEAK1 Y635 phosphorylation regulates cell migration
through association with Tensin3 and integrins. *Journal of Cell Biology, 221*(8), 18.
doi:10.1083/jcb.202108027

Graphical abstract:

Figure 1. Manhattan plot of PCa GWAS meta-analysis. The genetic regions containing top SNPs related to PCa are depicted. The red dashed line signifies the genome-wide significance threshold of 5.0×10^{-8}.

Figure 2. The top 10 significant cross-phenotype associations with PCa at a 5% FDR. The x-axis represents the P value of the correlation. BMI, body mass index.

Figure 3. Result of PW-MR on the associations between plasma proteins and the risk of PCa. (A) Volcano plot of PCa PW-MR study using deCODE (the left side) and UKB-PPP (the right side) cohorts. Annotated proteins passed the 5% FDR IVW P-value threshold. The blue and red colors represent a negative and positive effect, respectively.

(B) Venn diagram depicting proteins associated with PCa in deCODE and UKB-PPP.

(C) PhenoGram of PCa PW-MR study significant associations. The blue dots and the green dots represent the deCODE and UKB-PPP specific proteins, respectively. The red dot represents both simultaneously.

Figure 4. Colocalization plot of SERPINA3 variants associated with PCa in deCODE and UKB-PPP. Variants are color-coded based on their linkage disequilibrium (LD) with the lead SNP (the variant with the lowest p-value). The lead SNP is highlighted in red. Other variants are colored from blue to yellow, indicating decreasing LD with the lead SNP.

Figure 5. Functional annotation of the genetic architecture of PCa. (A) Biological processes and (B) KEGG pathway analysis of the 193 unique proteins identified in deCODE and UKB-PPP.